Cataracts and presbyopia, common age-related eye conditions, lead to vision impairment due to the destabilization and aggregation of crystallin proteins within the eye lens. Current treatments primarily involve surgical intervention, which can be invasive and costly. There is a need for non-surgical therapeutic options that can prevent or delay the progression of these conditions.

ViewPoint Therapeutics is developing a novel class of crystallin stabilizers designed to address the underlying molecular mechanisms of cataract formation and presbyopia. Their approach focuses on enhancing the stability of crystallin proteins in the eye lens, preventing their aggregation and maintaining lens transparency. By targeting the root cause of these conditions, ViewPoint aims to offer a non-invasive therapeutic alternative that can prevent or slow down vision impairment associated with aging and environmental factors. This technology has the potential to improve the quality of life for individuals at risk of developing cataracts or presbyopia, offering a proactive approach to vision care.

Small-molecule therapeutics designed to bind and stabilize crystallin proteins

Targeted approach to prevent protein aggregation and maintain lens transparency

Potential for topical administration via eye drops

Preclinical studies demonstrating efficacy in stabilizing crystallin proteins

The primary target audience includes individuals at risk of developing cataracts or presbyopia, as well as those in early stages of these conditions, seeking non-surgical treatment options.